Duration of treatment with 5-aminosalicylic acid compounds.

about

Optimal Endpoint of Therapy in IBD: An Update on Factors Determining a Successful Drug Withdrawal Pharmacokinetics and safety of single and multiple doses of Asacol tablets in Japanese healthy volunteers.

P2860

Q26801119-895B99EA-E241-425A-ADDB-8F5D5BE4C2BF Q43281007-23DB32E6-887C-4B5A-B4F1-17D47B98E418

P2860

Duration of treatment with 5-aminosalicylic acid compounds.

Item

http://www.wikidata.org/entity/Q36914360

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

2007年论文

@zh

2007年论文

@zh-cn

name

Duration of treatment with 5-aminosalicylic acid compounds.

@en

type

Item

label

Duration of treatment with 5-aminosalicylic acid compounds.

@en

prefLabel

Duration of treatment with 5-aminosalicylic acid compounds.

@en

P1476

Duration of treatment with 5-aminosalicylic acid compounds

@en

P2093

T Moshkovska

http://www.w3.org/2001/XMLSchema#string

P2860

A controlled therapeutic trial of long-term maintenance treatment of ulcerative colitis with sulphazalazine (Salazopyrin).

Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.

Users' guides to the medical literature. II. How to use an article about therapy or prevention. B. What were the results and will they help me in caring for my patients? Evidence-Based Medicine Working Group.

Guidelines for the management of inflammatory bowel disease in adults.

Randomised controlled trial of azathioprine withdrawal in ulcerative colitis.

Double-blind withdrawal trial of azathioprine as maintenance treatment for Crohn's disease.

Acute colitis in a district general hospital.

Quality of life in patients with established inflammatory bowel disease: a UK general practice survey.

Colorectal cancer prevention in ulcerative colitis: a case-control study.

CONTROLLED TRIAL OF SULPHASALAZINE IN THE TREATMENT OF ULCERATIVE COLITIS.

P304

4310-4315

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3748/WJG.V13.I32.4310

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

John F. Mayberry

P577

2007-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17708602

http://www.w3.org/2001/XMLSchema#string

P932

4250855

http://www.w3.org/2001/XMLSchema#string

Duration of treatment with 5-aminosalicylic acid compounds.

about

P2860

P2860

Duration of treatment with 5-aminosalicylic acid compounds.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P932